NYMC Faculty Publications
Lack of Evidence of Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure and Reduced Ejection Fraction Discharged on Spironolactone
DOI
10.1016/j.ijcard.2016.11.006
Journal Title
International Journal of Cardiology
First Page
462
Last Page
466
Document Type
Article
Publication Date
January 2017
Department
Medicine
Abstract
BACKGROUND: Therapy with evidence-based heart failure (HF) medications has been shown to be associated with lower risk of 30-day all-cause readmission in patients with HF and reduced ejection fraction (HFrEF). METHODS: We examined the association of aldosterone antagonist use with 30-day all-cause readmission in this population. Of the 2443 Medicare beneficiaries with HF and left ventricular EF
Recommended Citation
Lam, P., Dooley, D., Inampudi, C., Arundel, C., Fonarow, G., Aronow, W. S., Ahmed, A., & Ahmed, A. (2017). Lack of Evidence of Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure and Reduced Ejection Fraction Discharged on Spironolactone. International Journal of Cardiology, 227, 462-466. https://doi.org/10.1016/j.ijcard.2016.11.006
Comments
Please see the work itself for the complete list of authors.